Anavex Life Sciences Corp (AVXL)

[Hoskuld]

Drugs are not priced based on cost-to-produce. Biogen's COGS for Avonex, which at one point was selling $2b per year, was ~10%. The crystalized formula that I gave you as an example, Ohtuvayre, is also not at all expensive to produce. Even at $30K per year, which I don't think will be the pricing for 2-73 for AD, it would still be vastly cheaper than the mabs which would cost roughly the same - but then have the added costs that come with being a parenteral.